Pharmac agrees to fund nusinersen for those with spinal muscular atrophy
(New Zealand Herald)

By RNZ New medicines for those with a rare spinal disease and people at risk of anaphylaxis are set to be publicly funded.Pharmac is looking at funding adrenaline auto-injectors, such as EpiPens, for people who are at risk of...